Jiangsu Kanion Pharmaceutical Co Ltd (600557) — Cash Flow-to-Debt Ratio
Jiangsu Kanion Pharmaceutical Co Ltd (600557) has a Cash Flow-to-Debt Ratio of 0.11x as of September 2025, meaning its operating cash flow of CN¥201.83 Million could theoretically repay 0% of its total liabilities (CN¥1.83 Billion) in one year. See Jiangsu Kanion Pharmaceutical Co Ltd free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Jiangsu Kanion Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio (2001–2024)
Historical debt coverage capacity for Jiangsu Kanion Pharmaceutical Co Ltd across 24 annual periods. For the full cash flow conversion analysis, see cash efficiency ratio of Jiangsu Kanion Pharmaceutical Co Ltd.
Annual Cash Flow-to-Debt Ratio for Jiangsu Kanion Pharmaceutical Co Ltd (2001–2024)
Year-by-year debt coverage analysis for Jiangsu Kanion Pharmaceutical Co Ltd. Check Jiangsu Kanion Pharmaceutical Co Ltd (600557) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.32x | CN¥702.49 Million | CN¥2.20 Billion | ▼ -43.0% |
| 2023 | 0.56x | CN¥972.32 Million | CN¥1.74 Billion | ▲ +4.7% |
| 2022 | 0.53x | CN¥995.94 Million | CN¥1.86 Billion | ▼ -9.0% |
| 2021 | 0.59x | CN¥908.30 Million | CN¥1.55 Billion | ▲ +50.2% |
| 2020 | 0.39x | CN¥701.10 Million | CN¥1.79 Billion | ▼ -14.5% |
| 2019 | 0.46x | CN¥925.73 Million | CN¥2.02 Billion | ▲ +23.0% |
| 2018 | 0.37x | CN¥636.39 Million | CN¥1.71 Billion | ▲ +74.9% |
| 2017 | 0.21x | CN¥382.93 Million | CN¥1.80 Billion | ▲ +8.4% |
| 2016 | 0.20x | CN¥299.02 Million | CN¥1.52 Billion | ▼ -45.4% |
| 2015 | 0.36x | CN¥514.80 Million | CN¥1.43 Billion | ▲ +84.3% |
| 2014 | 0.19x | CN¥311.54 Million | CN¥1.60 Billion | ▼ -24.8% |
| 2013 | 0.26x | CN¥388.11 Million | CN¥1.50 Billion | ▲ +80.1% |
| 2012 | 0.14x | CN¥212.11 Million | CN¥1.47 Billion | ▲ +76.5% |
| 2011 | 0.08x | CN¥90.19 Million | CN¥1.11 Billion | ▼ -63.6% |
| 2010 | 0.22x | CN¥166.40 Million | CN¥743.19 Million | ▲ +476.0% |
| 2009 | -0.06x | CN¥-21.87 Million | CN¥367.23 Million | ▼ -136.3% |
| 2008 | 0.16x | CN¥58.39 Million | CN¥355.85 Million | ▼ -16.2% |
| 2007 | 0.20x | CN¥92.73 Million | CN¥473.81 Million | ▼ -20.4% |
| 2006 | 0.25x | CN¥108.98 Million | CN¥443.19 Million | ▲ +29.1% |
| 2005 | 0.19x | CN¥101.44 Million | CN¥532.62 Million | ▲ +225.8% |
| 2004 | 0.06x | CN¥21.68 Million | CN¥370.88 Million | ▲ +37.8% |
| 2003 | 0.04x | CN¥17.13 Million | CN¥403.56 Million | ▼ -64.7% |
| 2002 | 0.12x | CN¥11.15 Million | CN¥92.69 Million | ▼ -40.7% |
| 2001 | 0.20x | CN¥21.02 Million | CN¥103.61 Million | — |